No Data
No Data
Both Individual Investors Who Control a Good Portion of Allgens Medical Technology CO., LTD. (SHSE:688613) Along With Institutions Must Be Dismayed After Last Week's 15% Decrease
Allgens Medical Technology's Unit Gets Production License for Artificial Bone Repair Plant
Allgens Medical Technology Pays 7.6 Million Yuan in Taxes, Overdue Fees
OJ Medical (688613.SH): The subsidiary's newly added production line for artificial bone repair materials has obtained a medical instrument production license through commissioned production.
On September 9th, Ojinge Medical (688613.SH) announced that its wholly-owned subsidiary, Weifang Ojinge Health Technology Co., Ltd., recently received the approval of the Shandong Provincial Drug Administration to issue a "Medical Equipment Production License". The newly added production line for artificial bone repair materials has passed the compliance inspection of the medical equipment production quality management regulations. The annual production capacity of this production line that passed the compliance inspection of the medical equipment production quality management regulations is 2 million boxes of mineralized collagen artificial bone repair materials. Weifang Ojinge Health Technology Co., Ltd. has obtained the "Medical Equipment Production License", and it can comply with the regulations, rules, and norms.
Aokang Medical (688613.SH): Total supplemental tax and overdue fines amount to 7.5549 million yuan.
Grain Long Hui September 9th, Aojing Medical (688613.SH) announced that the company recently paid a total of 7.5549 million yuan in taxes and late fees. On August 7, 2024, the company received a reminder from the Fifth Tax Office of the Beijing Municipal Taxation Bureau of the State Administration of Taxation regarding the list of tax risk issues from January 1, 2022, to December 31, 2023. After a self-inspection, the company found that it needed to pay 2.5753 million yuan in corporate income tax for 2022 and 4.1807 million yuan for 2023, with an additional 0.7989 million yuan in late fees (as of the actual payment date), making a total of 755.4 million yuan to be paid.
OJ Medical (688613.SH): BioVeda plans to reduce its shareholding by no more than 1%.
Gelonghui, September 9th, Aojing Medical (688613.SH) announced that the company has recently received a notification letter from BioVeda regarding the shareholding reduction plan. Due to its own fund arrangement, BioVeda will reduce its shareholding through centralized competitive bidding and block trades according to the market conditions. BioVeda plans to reduce the shareholdings of Aojing Medical by no more than 1,355,515 shares, accounting for 1% of the total shareholdings of Aojing Medical. Among them, for those reduced through centralized competitive bidding, it shall be within 3 months after the end of 15 trading days from the date of the release of the shareholding reduction plan (October 1, 2024).
No Data
No Data